The volatility in gross margin, ranging from 41.8% to 73.0% over ten quarters, reflects the complex, high-variable-cost nature of autologous cell therapy manufacturing. The recent stabilization above 60% is a positive signal that the company is managing its per-patient production costs more effectively as volume scales. However, the operating margin only turned positive at 14.9% in 2026Q2, indicating that significant fixed costs in R&D and SG&A still require substantial revenue growth to achieve sustainable profitability.

The shift from a deeply negative ROIC of -19.6% in 2024Q1 to a positive 5.6% in 2026Q2 is driven by the dramatic improvement in operating margin, which swung from -125.4% to +14.9% over the same period. This indicates the business model is transitioning from a pure cash-burn phase to one where revenue growth is outpacing the expansion of its cost base. The sustainability of this positive ROIC is contingent on maintaining gross margins and continuing to scale the commercial infrastructure without a proportional increase in operating expenses.

The improvement in the CCC from 99 to 21 days suggests Legend Biotech is managing its receivables and payables more efficiently as commercial operations mature. However, the large negative working capital change in the cash flow statement reveals that the underlying asset growth—likely inventory for manufacturing and receivables from expanding sales—is consuming cash faster than the cycle metrics imply. This disconnect highlights that while the business is becoming more efficient on a per-cycle basis, the absolute cash required to fund its growth trajectory remains substantial.

The deleveraging trend, with D/E falling from 0.41 in 2025Q4 to 0.23 in 2026Q2, appears driven by equity issuance and retained earnings growth rather than debt repayment. The dramatic improvement in interest coverage from negative values to 288.50 is a direct result of the company generating positive operating income for the first time in the dataset. This financial flexibility is crucial for funding the ongoing manufacturing build-out and pipeline expansion without straining the balance sheet.

The high quick ratio, nearly matching the current ratio, indicates that the company's liquidity is not dependent on inventory, which is a positive sign given the specialized nature of its cell therapy products. The decline in the current ratio from 5.66 to 3.04 over two years reflects a strategic shift from holding excess cash to investing in property, plant, and equipment for manufacturing capacity. This level of liquidity appears adequate to support near-term operations and capital expenditures, but investors should monitor the rate of cash burn relative to revenue growth.